The maker of cannabis-derived medications, including Sativex and Epidiolex, recorded a net loss for the quarter of $50.1 million compared with a year-ago net loss of $69.5 million.
GW Pharma trades on the Nasdaq under the ticker symbol GWPH.
Epidiolex, Sativex maker GW Pharmaceuticals reports Q1 revenue, loss improvement
Latest Headlines
- Cannabis tech firm Tilt Holdings gets new $10 million credit line
- Marijuana brand Old Pal gets $8M infusion from consumer products firm
- Cannabis cultivation giant buys second garden center this week
- Denver approves first marijuana retailer to work with licensed delivery service
- PA court: Medical cannabis regulators must handle application redactions
- Canadian cannabis sales reach new record of CA$313 million in May
- Cannabis retailer High Tide continues US e-commerce acquisition spree
- Court approves Canadian marijuana producer CannTrust’s restructuring plan
- Canopy Growth sued by Cointreau over cannabis beverage name
- Cannabis producer Organigram sees sales rebound in third quarter
